Jove
Visualize
Contact Us

Related Experiment Videos

Idiopathic Giant Cell Myocarditis.

Leslie T. Cooper1, Yuji Okura

  • 1Division of Cardiovascular Medicine. Department of Internal Medicine, The Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Cooper.Leslie@mayo.edu

Current Treatment Options in Cardiovascular Medicine
|November 7, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk of cardiac dysfunction in patients receiving anthracyclines across breast cancer and hematologic malignancies: a single-center retrospective cohort study in Japan.

Heart and vessels·2026
Same author

Successful Steroid Pulse Therapy in Suspected Immune Checkpoint Inhibitor-Associated Myocarditis With Isolated Troponin Elevation.

JACC. Case reports·2025
Same author

Prefectural Survey on Anthracycline-Related Cardiomyopathy at the Start of the Basic Plan to Promote Cancer Control Programs - Phase 4.

Circulation reports·2025
Same author

Association of Medication Profiles, Including Polypharmacy, Guideline-Directed Medical Therapy, and Potentially Inappropriate Medications, With All-Cause Mortality in Older Adults With Heart Failure, With or Without Frailty and Disability.

Circulation journal : official journal of the Japanese Circulation Society·2025
Same author

Causes of applying Long-Term Care Insurance certification for patients with heart failure with systolic dysfunction.

Geriatrics & gerontology international·2025
Same author

Prefectural Survey on Immune Checkpoint Inhibitor-Associated Myocarditis at the Start of the Basic Plan to Promote Cancer Control Programs - Phase 4.

Circulation reports·2025
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Idiopathic giant cell myocarditis (IGCM) is a rare, often fatal heart condition affecting young people. Early diagnosis via biopsy and aggressive treatment, including potential heart transplantation, can improve survival rates.

Area of Science:

  • Cardiology
  • Immunology

Background:

  • Idiopathic giant cell myocarditis (IGCM) is a rare but serious cardiac condition.
  • It predominantly affects young individuals and is frequently fatal without prompt intervention.

Purpose of the Study:

  • To outline the diagnostic criteria and management strategies for IGCM.
  • To review current and emerging therapeutic options, including medical, surgical, and transplant-related interventions.

Main Methods:

  • Diagnosis confirmed by endomyocardial biopsy after excluding other cardiac diseases.
  • Management involves addressing congestive heart failure, arrhythmias, and heart block.
  • Treatment options range from standard heart failure medications to mechanical circulatory support and heart transplantation.

Related Experiment Videos

Main Results:

  • Standard heart failure therapies are initiated, with careful consideration of inotropic agents.
  • Pacemakers and implantable cardioverter-defibrillators are used for heart block and ventricular tachycardia.
  • Mechanical support devices and heart transplantation offer options for refractory cases, with a 5-year survival of 71% post-transplant.

Conclusions:

  • Aggressive immunosuppression, including regimens with muromonab-CD3, cyclosporine, and steroids, is under investigation.
  • Preliminary data suggest improved transplant-free survival with this intensive immunosuppressive approach.
  • IGCM requires a multidisciplinary approach, integrating medical, surgical, and potentially transplant strategies.